Gilead slides as 2026 outlook falls short of estimates

Shares of drugmaker Gilead GILD.O down 2.7% at $143.22 premarket

Co expects 2026 adjusted earnings per share of $8.45 to $8.85 compared with analysts' average expectations of $8.74, according to data compiled by LSEG

Gilead expects annual products sales of $29.6 billion to $30 billion vs estimate of $30.2 billion

"Despite that, the high hopes for launching PrEP drug Yeztugo may be manifesting in some of the post-market stock downside, as Q4 came in aligned with our expectations," RBC Capital Markets says

Quarterly sales of HIV prevention drug Yeztugo came in at $96 million vs estimate of $88 million

Stock fell 20% in 2025